CRIS.NASDAQCuris INC

Form 4: Curis Inc. Director Martyn D. Greenacre Acquires Stock Options

Sentiment:

Insider Transaction Report


Curis Inc. Director Martyn D. Greenacre was granted stock options for 6,800 shares of common stock.

Summary

  • Martyn D. Greenacre, a Director at Curis Inc. (CRIS), was granted 6,800 non-qualified stock options.
  • The options have an exercise price of $5.29 per share.
  • The transaction date was July 7, 2026, with an expiration date of July 6, 2036.
  • The options vest 100% on July 7, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock option grant to a director rather than significant financial results or strategic changes.

Positives

  • Director Martyn D. Greenacre received a stock option grant, indicating potential alignment of management interests with shareholders.
  • The stock options have a significant potential value if the company's stock price increases.

Risks

  • The value of the stock options is contingent on the future performance of Curis Inc.'s stock price.
  • There is a risk that the stock price may not appreciate sufficiently to make the options significantly valuable.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to executive compensation.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, like Curis Inc., to incentivize performance and align executive interests with long-term shareholder value.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Power of AttorneyMartyn D. Greenacre has appointed attorneys-in-fact to execute Section 16 reporting forms on his behalf.04/24/2026Facilitates timely and accurate filing of required SEC disclosures by designated individuals.

Stakeholder Impact

  • Shareholders: The stock option grant aligns director incentives with potential stock price appreciation, which can benefit shareholders if the company performs well.
  • Employees: This type of compensation for directors does not directly impact employees but reflects standard corporate governance practices.

Next Steps

  • Martyn D. Greenacre may exercise these options if the stock price exceeds the exercise price of $5.29.
  • The options will fully vest on July 7, 2027.

Key Dates

DateDescription
04/24/2026Date of execution of Power of Attorney by Martyn D. Greenacre.
07/07/2026Transaction date for the grant of stock options.
07/07/2027100% vesting date for the granted stock options.
07/06/2036Expiration date of the granted stock options.
07/09/2026Date of signature for the Form 4 filing.

Keywords

Curis Inc., CRIS, Form 4, Stock Options, Insider Trading, Director, SEC Filing, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.